Roivant says Phase 2 PHocus trial shows mosliciguat cuts pulmonary vascular resistance 56.3% in PH-ILD

Roivant reported positive Phase 2 results for inhaled mosliciguat in pulmonary hypertension tied to interstitial lung disease.

• Results are being presented today at the European Respiratory Society International Congress 2026.
• The trial showed meaningful improvement in lung blood-flow measures, walking capacity, and a cardiac stress biomarker versus placebo.
• Mosliciguat was well tolerated, with fewer cough reports than placebo, supporting differentiation from inhaled prostacyclin options.
• A Phase 3 trial in the same condition has started, moving the program into late-stage development with enrollment underway.